Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Crystalline vs Amorphous Rilzabrutinib in Healthy Participants
NCT06342700Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilzabrutinib in immune thrombocytopenia (ITP) and pemphigus vulgaris (PV) (4 arms), sponsored by Sanofi. Primary endpoints: Relative bioavailability as assessed by rilzabrutinib Cmax (Fasted), Relative bioavailability as assessed by rilzabrutinib AUClast (Fasted) and 1 more. Started Mar 2024; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT06342700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06342700.